Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Viridian TherapeuticsVRDN -0.52%49 Net Cash per Share is $5.06 as of Jun. 2026, which is 102% above its 10-year median of 2.50. GuruFocus rates VRDN with a GF Score™ of 49/100. The stock has 5 warning signs investors should review. Among 795 Biotechnology companies, Viridian Therapeutics ranks better than 55.72% on this metric.
Viridian Therapeutics (NAS:VRDN) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Viridian Therapeutics Net Cash per Share Related Terms
Viridian Therapeutics Net Cash per Share Historical Data
* Premium members only.
The historical data trend for Viridian Therapeutics's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VRDN vs BHVN, AGIO, SION: Net Cash per Share Comparison
For the Biotechnology subindustry, Viridian Therapeutics's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viridian Therapeutics Price-to-Net-Cash vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Viridian Therapeutics's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Viridian Therapeutics's Price-to-Net-Cash falls into.
Viridian Therapeutics Net Cash per Share Calculation
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Viridian Therapeutics's Net Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viridian Therapeutics (VRDN) has a Net Cash per Share of $5.06 as of Jun. 2026. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Viridian Therapeutics and its competitors. This is 102% above median its historical median of 2.50. Over the past decade, Viridian Therapeutics' Net Cash per Share has ranged from 0.60 to 7.38. According to the industry distribution chart, Viridian Therapeutics ranks #352 out of 795 companies in the Biotechnology industry, placing it in the top 44.3%.
Is Viridian Therapeutics' Net Cash per Share too high?
Viridian Therapeutics' current Net Cash per Share of $5.06 is 102% above median its 10-year median of 2.50. Over the past 10 years, this metric has ranged from a low of 0.60 to a high of 7.38. The Biotechnology industry median Net Cash per Share is 5.30. Viridian Therapeutics' value of $5.06 is 4.5% below this industry median. Based on the distribution chart, Viridian Therapeutics ranks #352 out of 795 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Viridian Therapeutics has a GF Score™ of 49/100, reflecting its overall financial health beyond just this single metric.
How does Viridian Therapeutics' Net Cash per Share compare to BHVN and AGIO?
According to the Biotechnology industry distribution chart, Viridian Therapeutics ranks #352 out of 795 companies for Net Cash per Share. This puts Viridian Therapeutics in the upper half of its industry. The industry median Net Cash per Share is 5.30. Viridian Therapeutics' value of $5.06 is 4.5% below this benchmark. Historically, Viridian Therapeutics' own Net Cash per Share has ranged from 0.60 to 7.38 over the past decade. While the company's 10-year median is 2.50 vs. the industry median of 5.30, Viridian Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Biotechnology company?
The median Net Cash per Share among Biotechnology companies is 5.30, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Viridian Therapeutics's current Net Cash per Share of $5.06 is 4.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Viridian Therapeutics and its competitors. For the Biotechnology industry, the median Net Cash per Share is 5.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Viridian Therapeutics's current Net Cash per Share is $5.06, which is 102% above median its own 10-year median of 2.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viridian Therapeutics stock overvalued right now?
Viridian Therapeutics (VRDN) has a current Net Cash per Share of $5.06. The current Net Cash per Share is $5.06, which is 102% above median its 10-year median of 2.50 and 4.5% below the Biotechnology industry median of 5.30. Viridian Therapeutics' overall GF Score™ is 49/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For Viridian Therapeutics (VRDN), the current Net Cash per Share is $5.06 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
49GF Score
Get the complete analysis for VRDN
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VRDN has been successfully added to your 
